In a lengthy shareholders' advice, beleaguered biosensor company Gradipore has donned not just the hair shirt but the hair suit admitting a "disappointing" $15.5-16 million loss and noting commitment to a "more effective and timely communication with all shareholders." [ + ]

Geneticists appear to have failed in their latest attempt to indict human grandmothers in the court of life for indirectly visiting menopause upon their daughters. [ + ]

Domesticated plant and animal genomes provide excellent material for the study of haplotypes and adaptation, according to Gane Ka-Shu Wong, deputy director of the Beijing Institute of Genomics. [ + ]

The administration of freebase cocaine to fruit flies has uncovered novel pathways central to the development of addiction and may eventually lead to the development of drugs to cure or prevent it. [ + ]

Africa's leading molecular geneticist told a forum on genetically modified organisms that poverty, not GM crops, posed the biggest threat to biodiversity around the world. [ + ]

Dr Klaus Amman is puzzled by the furore over pollen drift from genetically modified crops - "Pollen did not learn to fly with transgenes," he said. [ + ]

Australian-born Baylor geneticist Richard Gibbs believes rapid, low-cost sequencing is the key new technology required to keep the genomics revolution advancing. [ + ]

The danger that invertebrate and other forms of life in threatened environments, like tropical rainforests, may not survive climate change now appears more acute than previously thought.

'Post-genomic era' should be banned -- the genomic era has just started, according to Francis Collins, one of the leaders of the Human Genome Project. [ + ]

Victoria trails Queensland among state governments that are energetically supporting bioscience and needs to fine-tune its Bio 21 initiative, according to one of the bioIT industry's most unusual executives, Michael Armitage. [ + ]

Research by a Monash University academic into a family of proteins called serpins and their role in controlling cell growth has earned him the 2003 Victorian Premier's Award for Medical Research.

Australian Cancer Technology (AustCancer)’s anti-cancer vaccine Pentrix is about to enter critical Phase II trials for its efficacy as a disease delay compound against cancer. [ + ]

Perth oil exploration company-turned-biotech EQiTX has signaled a new level of intent for its ambitions with the appointment to its board of ex-Pfizer R&D director Dr Kevin Fahey. [ + ]

Select Vaccines, the first biotech floating an IPO in 2003, has shown the way for investors with a 150 per cent oversubscription from the money market. [ + ]

Researchers associated with Victorian-based AGT Biosciences have landed a $AUD4.4 million grant from the US National Institutes of Health to fund its human gene discovery research. [ + ]